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Abstract 
Introduction: The objective of this study was to analyse the effects of the first three years of treatment with recombinant human insulin-
like growth factor 1 (rhIGF-1) in patients from the Polish population.
Material and methods: Twenty-seven children (22 boys and five girls) aged 2.8 to 16.0 years old were qualified for treatment with rhIGF-1 
(mecasermin) in different treatment centres, according to Polish criteria: body height below –3.0 SD and IGF-1 concentration below percentile 
2.5 with normal growth hormone (GH) levels. Mecasermin initial dose was 40 μg/kg bw twice a day and was subsequently increased to 
an average of 100 μg/kg bw twice a day. Body height, height velocity, weight, body mass index (BMI), and adverse events were measured.
Results: Mecasermin treatment resulted in a statistically significant increase in body height (1.45 ± 1.06 SD; p < 0.01) and height velocity 
in comparison with pre-treatment values. The biggest change in height velocity happened during the first year and diminished during 
subsequent years. Body weight and BMI also increased significantly after treatment (1.16 ± 0.76 SD and 0.86 ± 0.75 SD, respectively; 
p < 0.01). Eight patients reported adverse events. These were mild and temporary and did not require treatment modification except in 
two patients. 
Conclusions: Treatment with rhIGF-1 was effective and safe in Polish patients with primary IGF-1 deficiency. It had a clear beneficial ef-
fect on the height of the patients and significantly accelerated the height velocity, particularly in the first year of treatment. (Endokrynol 
Pol 2019; 70 (1): 20–27)
Key words: insulin-like growth factor-1 (IGF-1); growth hormone insensitivity; IGF-1 deficiency; short stature; growth-promoting therapy; 
mecasermin; Poland
Streszczenie
Wstęp: Celem badania była analiza efektów pierwszych 3 lat leczenia preparatem rekombinowanego ludzkiego insulinopodobnego 
czynnika wzrostu 1 (rhIGF-1) u pacjentów w populacji polskiej.
Materiał i metody: Do leczenia rhIGF-1 (mekaserminą) zakwalifikowano w różnych ośrodkach 27 dzieci (22 chłopców i 5 dziewcząt) 
w wieku 2,8–16,0 lat, zgodnie z polskimi kryteriami: wysokość ciała < –3,0 SD oraz stężenie IGF-1 < 2,5 centyla przy prawidłowym 
Prof. Andrzej Lewiński, Department of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital — Research Institute, 
Rzgowska Street 281/289, 93–338 Lodz, Poland, tel: +48 42 271 11 41, fax: +48 42 271 11 40, e-mail: alewin@csk.umed.lodz.pl
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severe primary IGF-1 deficiency with rhIGF-1 has been 
covered by a therapeutic program since 2009. The 
first results of treatment were described in a previous 
publication [4]. 
The authors of the present article discuss the 
therapeutic effects observed in the first three years 
of treatment with rhIGF-1 in patients from the Polish 
population.
Material and methods
All patients were qualified for treatment based on 
unified criteria for all treatment centres. Patients were 
diagnosed with severe primary IGF-1 deficiency ac-
cording to Polish criteria if they presented extremely 
short-stature, defined as body height below –3.0 SD for 
sex and age, and IGF-1 concentration below percentile 
2.5 for sex and age with normal GH levels (confirmed 
in the nocturnal surge and/or stimulation tests). The 
IGF-1 generation test was carried out in all patients to 
assess the insensitivity to GH. According to the standard 
most commonly used in Poland, the test was carried 
out for four days. The initial concentration of IGF-1 
was assessed, and then at 18:00 the growth hormone 
was administered subcutaneously for four consecutive 
days in a daily dose of 0.033 mg/kg bw. Subsequently, 
the concentration of IGF-1 was assessed in the morn-
ing. An increase of IGF-1 concentration of less than 15 
ng/ml indicated complete (severe) IGF-1 deficiency, 
a change ranging between 15-160 ng/ml suggested 
a partial IGF-1 deficiency, while a change greater than 
160 ng/ml excluded primary IGF-1 deficiency. Figure 1 
illustrates the technique for conducting the test.
The group of Polish patients described in this study 
are the first 27 children treated with rhIGF-1 in Poland 
and include 22 boys (81.48%) and five girls (18.52%). 
The average age at the start of treatment was 10.06 years 
(9.56 for boys, and 12.27 for girls); the youngest patient 
was 2.8 years old, and the oldest was 16.2 years old.
The average children’s body height expressed as 
SDS in relation to age and sex was -3.52 SD. The mean 
baseline concentration of IGF-1 expressed as SDS in 
Introduction
Primary deficiency of insulin-like growth factor-1 
(IGF-1) is a rare cause of short stature caused by 
impaired functioning of the growth hormone (GH) 
— IGF-1 axis. Patients suffering from the disease have 
low levels of IGF-1 despite normal or even elevated lev-
els of GH. The most striking form of IGF-1 deficiency is 
Laron syndrome, in which there is a receptor resistance 
to GH leading to IGF-1 secretion disorders.
IGF-1 was discovered as a hormone in the 1950s. It 
is a hormone with a peptide structure, similar to that 
of insulin, which consists of chains A and B, connected 
with peptide C. IGF-1 is produced mainly in the liver, 
but also in other tissues through a paracrine/autocrine 
mechanism. Its production is stimulated by GH. In the 
circulation, IGF-1 occurs mainly (> 99%) in the form 
bound to specific IGF binding proteins (IGFBPs) and 
their acid-labile subunit (ALS). It is an essential growth 
factor in the human body. The site of IGF-1 action is 
its specific receptor, IGF1R, which is a tyrosine kinase 
receptor that activates further intracellular transduc-
tion mediated by protein kinase B. IGF-1 influences 
the growth of most of the tissues in the body, espe-
cially skeletal, muscle, and cartilage. A 40% increase in 
GH-dependent growth results from the action of GH 
on maturing bones and the para/autocrine action of 
IGF-1. Thus, IGF-1 deficiency is related to the lower final 
height of the patient. Due to the mechanism of factor 
secretion, recombinant human GH (rhGH) therapy is 
not effective in patients with short stature caused by 
primary IGF-1 deficiency [1, 2]. 
Despite the discovery of IGF-1 in the 1950s, the 
description of its molecular structure was possible only 
in 1978. The 1980s brought about the development of 
a recombinant human IGF-1 (rhIGF-1) obtained by 
microbiological methods and the beginning of research 
on its effects and effectiveness in therapy [3]. 
The first preparation of rhIGF-1 (mecasermin, 
trade name Increlex) was registered for the treatment 
of short-statured patients in 2005 in the USA, and in 
2007 in Europe. In Poland, treatment of patients with 
stężeniu hormonu wzrostu (GH). Początkowa dawka mekaserminy wynosiła 40 μg/kg masy ciała (mc.) i była stopniowo zwiększana do 
średnio 100 μg/kg mc. 2 razy dziennie. Oceniano wysokość ciała, tempo wzrastania, masę ciała, wartość wskaźnika masy ciała (BMI) oraz 
zdarzenia niepożądane. 
Wyniki: Leczenie mekaserminą skutkowało statystycznie istotnym przyrostem wysokości ciała (1,45 ± 1,06 SD; p < 0,01) oraz tempa 
wzrastania w porównaniu z wartościami sprzed leczenia. Najwyższe tempo wzrastania zaobserwowano w pierwszym roku leczenia, 
zmniejszało się ono w latach kolejnych. Przyrosty masy ciała i BMI w trakcie leczenia również osiągały wartości istotne statystycznie (od-
powiednio 1,16 ± 0,76 SD and 0,86 ± 0,75 SD; p < 0,01). Zgłoszono wystąpienie 8 zdarzeń niepożądanych. Poza dwójką dzieci zdarzenia 
te były łagodne i przemijające, nie wymagały modyfikacji leczenia.
Wnioski: W populacji polskich dzieci z pierwotnym niedoborem IGF-1 leczenie z zastosowaniem rhIGF-1 było skuteczne i bezpieczne. 
Wykazano korzystny wpływ na wysokość ciała i znaczący wzrost tempa wzrastania, szczególnie w pierwszym roku leczenia. (Endokrynol 
Pol 2019; 70 (1): 21–27)
Słowa kluczowe: insulinopodobny czynnik wzrostu 1 (IGF-1); oporność na hormon wzrostu; niedobór IGF-1; niedobór wzrostu; 
terapia promująca wzrastanie; mekasermina; Polska
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relation to sex and age was –2.17 SD. Twenty-five of 
the patients were prepubescent, and two of them were 
at Tanner’s stage II of sexual development. One of the 
children did not have a body height lower than –3.0 
SD for sex and age, and the other one did not have 
initial IGF-1 below percentile 2.5 for age and sex. One 
of the children’s pre-treatment height velocity was 7.5 
cm/year, despite which, the child still had short stature 
with body height SDS –3.32. Detailed characteristics of 
the group are presented in Table I.
All patients started treatment with a relatively low 
dose of the drug, and it was successively increased dur-
ing the following months of treatment. The initial dose 
of mecasermin was 40 μg/kg bw twice a day, which is 
the minimum dose in the algorithm recommended in 
Poland. After 12 months, the average dose increased 
to 80 μg/kg bw (minimum 60, maximum 120 μg/kg bw) 
twice a day to finally reach an average value of 100 
(80–120) μg/kg bw twice a day. The maximum dose of 
mecasermin used was 120 μg/kg bw twice a day.
The treatment of all children was monitored in the 
same way in each of the treatment centres. Control visits 
took place every three months. The concentration of 
IGF-1, IGFBP-3, and fasting glucose were assessed during 
each control visit. Every six months, the concentrations 
of thyrotropin (TSH), free thyroxine (FT4), and serum 
electrolytes were evaluated. Additionally, every 12 months 
an oral glucose tolerance test was carried out, the percent-
age of glycated haemoglobin was determined, cardiac 
consultation with echocardiography and laryngological 
consultation with audiometric examination were carried 
out, and bone age was assessed. Depending on clinical 
indications, Polish guidelines recommend performing 
neuroimaging in patients once a year. Treatment of two 
of the patients was terminated early due to side effects of 
the treatment — after 24 and 30 months, respectively. The 
analysed group reaching the end of the study (36 months 
of treatment) consisted of 25 children.
For further analyses, the group was later divided 
in two according to maximal GH concentration and 
baseline IGF-1 SDS by the median, which was 19.1 
ng/ml in the case of GH peak and –2,22 SD in the case 
of IGF-1 SDS. 
Methods of statistical analysis
Statistical analysis was performed in the Stata 11.0 
program. The Shapiro-Wilk test was used to verify the 
normality of distributions. Since the distribution of 
most variables deviated from the normal distribution, 
nonparametric methods were used to test the differenc-
es. The Mann-Whitney U test was used to analyse the 
differences in mean values, and relationships between 
continuous variables were examined by correlation and 
regression analysis.
The analysis of categorical variables was carried 
out with contingency table methods, using Pearson’s 
chi-squared test of independence. Because most vari-
ables did not have a normal distribution, the nonpara-
metric Spearman correlation was used to assess the 
dependence of continuous variables. In multivariate 
correlations, the effect of various factors on the depend-
ent variable was analysed while controlling two factors, 
such as treatment duration and dose. An analysis of 
covariance (ANCOVA) was also performed, which per-
mitted the assessment of how a given factor influences 
the dependent variable while controlling for the effects 
of covariates. Statistical significance was considered at 
p values ≤ 0.05.
Results
The effect of mecasermin treatment on the body 
height of patients
The whole group showed an improvement in body 
height expressed as SDS in relation to sex and age. 
The mean body height SDS was –3.52 ± 0.82 before 
treatment, and –2.25 ± 0.91 after 36 months of treat-
ment (p < 0.01). The average increase in height was 
Table I. Group characteristics 
Tabela I. Charakterystyka grupy badanej
Parameter Mean Min Max
Age [years] 10.06 2.80 16.20
Body height, SDS −3.52 −6.47 −2.33
Body weight, SDS −3.14 −5.77 −1.19
BMI, SDS −1.79 −5.49 0.54
IGF-1, SDS −2.17 −2.59 −1.56
Max. GH concentration [ng/ml] 24.37 10.70 50.10
Fasting glucose [mg/dl] 81.28 62.00 96.00
HbA1c 5.31% 4.78% 5.90%
Height velocity [cm/year] 4.55 0.90 7.50
IGF-1 measurements
9:00
18:00
1 2 3 4 5/*
Last IGF-1 measurements
9:00
/* Last IGF-1 measurement. 15 hours after last GH dose
DIGF-1 £ 15 ng/ml after GH administration suggests severe primary IGF-1 
deficiency
DIGF-1 > 15 & < 160 ng/ml suggests partial IGF-1 deficiency
DIGF-1 ≥ 160 ng/ml excludes IGF-1 deficiency
Figure 1. IGF-1 generation test
Rycina 1. Test generacji IGF-1
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1.45 ± 1.06 SD. (Fig. 2). The apparent decrease in mean 
body height SDS change observed in the 21st month of 
therapy may be a result of not every site providing the 
results in this particular time point of the study. It has 
to be noted that while strictly controlled by the rules of 
a state-funded therapeutic program, the study was not 
a clinical trial, there was thus some area for freedom in 
setting the control timepoints in any given study site.
There was also an improvement in the height 
velocity. Starting at an average of 4.5 ± 1.6 cm/year, 
the greatest improvement occurred in the first year 
of treatment, when the average value was 7.8 ± 1.9 
cm/year. In the second year of treatment, the average 
height velocity was 6.3 ± 0.8 cm/year, whereas in the 
third year of treatment the mean height velocity was 
4.9 ± 1.8 cm/year (Fig. 3).
The effect of mecasermin treatment on the body 
weight of patients
There was a statistically significant relationship between 
the treatment time and the body weight of patients, ex-
pressed as SDS in relation to sex and age. During three 
years of treatment the body weight SDS increased from 
–3.14 ± 1.14 to –1.95 ± 0.99 (p < 0.01). The mean weight 
gain in the whole group was 1.16 ± 0.76 SD (Fig. 4). 
The body mass index (BMI) of the treated children 
also changed significantly. During three years of treat-
ment the BMI SDS for sex and age increased from 
–1.79 ± 1.30 to –0.91 ± 0.99 (p < 0.01). The average 
increase in BMI was 0.86 ± 0.75 SD (p < 0.01) (Fig. 5).
The relationship between the change in height 
and body weight during treatment with respect to the 
pre-treatment concentration of GH and IGF-1 in treated 
children was tested. 
The statistical analysis also examined the effect of 
certain factors, such as maximum GH concentration 
and baseline IGF-1, on the dependent variable when 
controlling two other factors, one of which was always 
the treatment duration, while the second one was 
mecasermin dose. 
Both the partial correlation coefficients and the p-
values were obtained while controlling the treatment 
time and the medication dose.
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Figure 2. Change of body height SDS during treatment
Rycina 2. Zmiana wartości SDS wysokości ciała podczas terapii
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Figure 3. Height velocity during treatment
Rycina 3. Tempo wzrastania podczas terapii
Time of treatment (months)
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Figure 4. Change of body weight SDS during treatment
Rycina 4. Zmiana wartości SDS masy ciała podczas terapii
Time of treatment (months)
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Figure 5. Change of BMI SDS during treatment
Rycina 5. Zmiana wartości BMI SDS podczas terapii
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The correlation between peak GH concentration 
and change in body height was significant (r = 0.93, 
p < 0.01), as well as the correlation between peak GH 
concentration and change in body height SDS (r = 0.76, 
p < 0.01). The correlation between peak GH concentra-
tion and an increase of body weight was also significant 
(r = 0.76, p < 0.01), similarly to the change in body 
weight SDS (r = 0.41, p < 0.01). 
The correlation between baseline IGF-1 concentra-
tion and change in body height was not significant 
(r = 0.93, p = 0.81). The correlation between baseline 
IGF-1 SDS and increase of body height SDS was also 
not significant (r = 0.48, p = 0.58). Interestingly, the 
correlation between baseline IGF-1 and body weight 
increase during three years of treatment occured only 
in the case of body weight expressed in kilograms 
(r = 0.78, p ≤ 0.01); for body weight expressed as SDS 
for age and sex, the p-value was 0.86. 
In patients with initially higher levels of GH 
(≥ 19.1 ng/ml), increases in height and body weight were 
greater than in patients with lower GH (< 19.1 ng/ml). 
The difference was statistically significant (p < 0.01) 
(Fig. 6 and 7).
A similar relationship occurred between the change 
in body weight and BMI, and the initial concentration 
of IGF-1 expressed as SDS for sex and age. Patients 
with more severe IGF-1 deficiency (< –2.22 SD) in-
creased their body weight and BMI less than children 
with initially higher IGF-1 concentrations (≥ –2.22 SD) 
(Fig. 8 and 9). The difference was statistically significant 
(p < 0.01). 
Figure 6. Change of body height SDS during treatment, depending 
on pre-treatment GH peak. Diagram of means and confidence 
interval (95%)
Rycina 6. Zmiana wartości SDS wysokości ciała podczas terapii 
w zależności od wydzielania GH przed leczeniem
Time of treatment (months)
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Figure 7. Change of body weight SDS during treatment, 
depending on pre-treatment GH peak. Diagram of means  and 
confidence interval (95%)
Rycina 7. Zmiana wartości SDS masy ciała podczas terapii 
w zależności od wydzielania GH przed leczeniem
Figure 8. Change of body weight during treatment, depending on 
IGF-1 SDS before treatment. Diagram of means  and confidence 
interval (95%)
Rycina 8. Zmiana masy ciała podczas terapii w zależności 
od wartości IGF-1 SDS przed leczeniem
Time of treatment (months)
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Figure 9. Change of BMI SDS during treatment, depending on 
IGF-1 SDS before treatment. Diagram of means
Rycina 9. Zmiana BMI SDS podczas terapii w zależności 
od wartości IGF-1 SDS przed leczeniem
Time of treatment (months)
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Side effects
Treatment side effects were reported in eight patients 
(29.63%).
Two patients (7.41%) experienced hypoglycaemia 
during the sixth month of treatment. In one of them, 
this was associated with a deterioration of appetite 
and a reduction in the number of meals taken. A blood 
glucose level of 56 mg/dl was observed once. After 
returning to the previous diet, no further episodes of 
hypoglycaemia were noted. The second patient was 
treated with a maximal dose of 120 μg/kg bw twice 
a day. During the sixth month of treatment, a blood 
glucose level of 40 mg/dl was observed once. No dose 
adjustment was required, and no further hypoglycae-
mia episodes were noted.
Two patients (7.41%) had hyperlipodystrophy 
changes in the sites of injections. One patient (3.7%) 
developed hypertrophy of the lymphatic tissue of the 
pharyngeal tonsils; the same patient also had an in-
crease in scoliosis diagnosed before. One patient (3.7%) 
reported headaches during treatment. Another patient 
(3.7%) reported hair loss as an adverse event during the 
treatment. The connection between the event and the 
therapy is, however, unclear.
Three patients finished their treatment in the course 
of the study.
Two patients terminated treatment early due to side 
effects. One of the patients showed thickening of the 
ventricular septum in echocardiographic examination. 
The treatment was discontinued between the fifth and 
seventh month of treatment, for the duration of the 
cardiac diagnosis. The patient was scheduled for heart 
valve implantation surgery. Eventually, treatment was 
discontinued after 30 months of therapy. The other patient 
suffered from conductive hearing loss due to chronic 
exudative otitis media. In addition, the patient remained 
under orthopaedic care because of left-sided scoliosis in 
the Th6-12 section of the spine. Due to the progression of 
the curve from 18 degrees in 2009 to 41 degrees in 2011, the 
treatment was discontinued in the second year of therapy. 
One of the patients ended her treatment after three 
years, having reached a bone age indicating the end 
of therapy (14 years). The patient’s initial body height 
expressed as SDS for sex and age was –4.00 SD, and her 
final height after treatment was –3.05 SD, which means 
a change in body height of +0.95 SD.
Discussion
The aim of the study was to present the results of treat-
ment with rhIGF-1 of the first patients in the Polish 
population.
When comparing the treatment benefits with the 
occurrence of side effects, attention should be paid to 
the differences in the qualification for treatment with 
mecasermin in the United States and in European 
Union countries. The most important of these is the 
concentration of IGF-1 expressed as SDS in relation to 
age and sex. In the US, short-statured children with 
body height SDS ≤ –3.0 and IGF-1 SDS ≤ –3.0 are quali-
fied for the treatment. Patients with GH gene deletion 
in which growth hormone-neutralising antibodies 
have been generated are also eligible for treatment. 
In Europe, the use of IGF-1 is recommended for the 
long-term treatment of children with severe primary 
IGF-1 deficiency, referred to as body height SDS ≤-3.0, 
with a baseline IGF-1 below percentile 2.5 for sex and 
age. The European definition describes in more detail 
the level of growth hormone and excludes secondary 
forms of IGF-1 deficiency [5, 6]. Also, in the population 
of Polish patients, there were no children with the clas-
sic phenotype of Laron syndrome. Additionally, two of 
the patients qualified for treatment did not fully meet 
the criteria for inclusion in the therapeutic program 
in Poland. 
This can be explained by the more liberal approach 
of the qualifying team in the initial period of the thera-
peutic program, which could have resulted from a small 
group of treated patients. The study sums up the first 
Polish experience with IGF-1 deficiency treatment, with 
all the patients taking part in the study being the first 
patients ever to be qualified for the treatment in Poland.
When discussing the qualification of children for 
rhIGF-1 treatment, one should refer to the controversy 
caused by the somatomedin generation test. Although 
most paediatric endocrinologists surveyed in Europe 
carried out this test in recent years, and in 45% of cases 
the result was necessary to start treatment, its predic-
tive value is low (sensitivity 77–91%, specificity ≤ 97%). 
According to some authors, due to the limitations of 
the test in the diagnosis of the most severe IGF-1 defi-
ciencies resulting from GH insensitivity syndrome, its 
usefulness for the diagnosis of milder cases is question-
able [7]. Another problem is the lack of a unified testing 
methodology in different centres. This was not an issue 
with the Polish group, due to unified recommendations 
regarding the test method. The researchers did not 
have, however, control over the laboratory method for 
IGF-1 determination. The patients’ blood samples were 
not assessed in one central laboratory, but instead they 
were tested in the individual centres where treatment 
was conducted, which could lead to discrepancies in the 
assessment and interpretation of the results obtained.
It is also worth noting that the median value of 
maximal GH concentrations (measured during spon-
taneous nocturnal secretion or after pharmacological 
stimulation) of 19.1 ng/ml suggests GH-insensitivity in 
this group of patients. 
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In every study evaluating the long-term effects of 
rhIGF-1 treatment, a significant increase in the height 
velocity was observed in the first year of treatment 
with a slowdown in subsequent years [5, 8, 9]. A clear 
beneficial effect of rhIGF-1 therapy on the height of the 
treated patients was found, but most of them will not 
reach a final height within the population standard. 
The height velocity in the described group of Polish 
patients (approximately 8 cm/year in the first year of 
treatment) is similar to that in the groups described by 
other authors [5, 8, 9]. 
When assessing the results of treatment in terms of 
body height, the impact of patient compliance cannot be 
neglected. The lack of dedicated pens for the drug and 
the need to perform two injections per day significantly 
reduced compliance for therapy over time in some 
patients, as was demonstrated by the amount of drug 
returned at control visits. During the treatment, only 
the endocrine form of IGF-1 is supplemented, which 
may affect the final effects of treatment by disturbing 
paracrine and autocrine secretion. It has been proven 
that the results of treatment are not affected by the 
lack of exogenously administered IGFBP-3 and ALS. 
A single daily dose of rhIGF-1/rhIGFBP-3 is effective in 
maintaining the physiological concentration of IGF-1 
in the absence of ALS. RhIGF-1 injections twice a day 
provide similar effects despite deficiency of both ALS 
and IGFBP-3, the concentration of which is not cor-
rected by IGF-1 treatment [1]. 
The literature describes many potential side effects 
of treatment. The most common of these are hypogly-
caemia, headache, and lipohypertrophy at the site of 
drug administration.
The increased risk of hypoglycaemia results 
from the similarity between the rhIGF-1 and insulin 
molecules. The literature, however, indicates effec-
tive prevention of glycaemic decline through proper 
nutrition and administration of the drug with a meal 
[10, 11]. The incidence of at least one hypoglycaemic 
episode has been described in 14% [12] to as many as 
49% [9] of patients, including 10% of episodes of severe 
hypoglycaemia accompanied by seizures in 6% of cas-
es. However, in the study of Chernausek et al. [9], 32% 
of children reporting hypoglycaemia experienced epi-
sodes of hypoglycaemia before starting the treatment. 
The higher numbers of episodes of hypoglycaemia in 
the aforementioned studies (especially Chernausek 
et al.) can be explained by patients presenting classic 
Laron syndrome phenotype, which was present in 
those groups. There were no such cases among the 
Polish patients. 
In the Polish group of patients, hypoglycaemia oc-
curred in 7.41% of patients; it was mild, transient, and 
did not require treatment modification.
Hypertrophy of the lymphatic tissue in patients 
treated with rhIGF-1 may be associated with sen-
sorineural hearing loss, snoring, and sleep apnoea 
syndrome due to hypertrophy of the palatine tonsils 
and the pharyngeal tonsil. In some patients this entails 
the need for adenotomy and/or tonsillectomy. Due to 
the incidence of ear, nose, and throat complications in 
previous studies, an audiometric test was included in 
the standard evaluation protocol during treatment with 
rhIGF-1. In the study by Chernausek et al. [9], 22% of 
patients had laryngological complications, and surgical 
intervention was necessary in 11%. In the Polish group, 
one patient (3.7%) presented hypertrophy of the lym-
phatic tissue of the pharyngeal tonsils. It is possible that 
this percentage was underestimated in both studies, 
due to the time needed to develop such side effects. 
Chernausek et al. [9] described lipohypertrophy at 
the injection site as a common (32%) local complication 
of treatment with rhIGF-1. It can be prevented, as with 
insulin, by changing the injection site during the next 
administration. In the Polish group, the problem was 
found in two patients (7.41%).
Other side effects described in the literature [5, 9, 
12] are much less common, and include orthopaedic 
problems, increased intracranial pressure, and kidney 
stones. Of those possible side effects, one of the patients 
presented an increase in the curve of scoliosis. One of 
the patients in the Polish group experienced hair loss, 
an adverse reaction not reported previously in the lit-
erature. Due to the lack of other reports on this subject, 
and the numerous reports on the beneficial effects of 
IGF-1 preparations on hair growth resulting from its 
anti-apoptotic action [13], coincidence of the symptom 
with rhIGF1 therapy cannot be ruled out.
Summary and conclusions
Until recently, rhGH was the only treatment option 
available for children with severe short stature. Cur-
rently, rhIGF-1 is an additional therapeutic option. It has 
been proven safe and effective in increasing the height 
velocity and in improving the final height in a very 
limited number of patients who have been confirmed 
to have primary IGF-1 deficiency.
The published data show that rhIGF-1 therapy in pa-
tients with primary IGF-1 deficiency significantly accel-
erates the height velocity in the first year of treatment. 
The velocity falls in subsequent years of treatment, but 
not to the level measured before therapy. Growth re-
sponse to rhIGF-1 is not as strongly expressed, nor is it 
maintained for as long as the response to GH in children 
with GH deficiency. Treatment has been shown to be 
effective, resulting in benefits in the form of increasing 
the patients’ body height SDS. 
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The therapy was safe. Except for two patients, side 
effects in the group of Polish patients were rare, mild, 
transient, and did not require treatment modifications. 
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